N-(alpha)-苄氧羰基-N-(epsilon)-叔丁氧羰基-L-赖氨酸琥珀酰亚胺基酯 | 3338-34-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 赖氨酸类衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(alpha)-苄氧羰基-N-(epsilon)-叔丁氧羰基-L-赖氨酸琥珀酰亚胺基酯
• 中文别名: 苄氧羰基-N'-叔丁氧羰基-L-赖氨酸琥珀酰亚胺酯；N-苄氧羰基-N'-叔丁氧羰基-L-赖氨酸琥珀酰亚胺酯；异硫氰酸荧光素酯；N-苄氧羰基-N\'-叔丁氧羰基-L-赖氨酸琥珀酰亚胺酯
• 英文名称: Z-Lys(-Boc)-Osu
• 英文别名: Z-L-Lys(Boc)-OSu；Z-Lys(-Boc)-ONSu；Z-Lys(boc)-osu；(2,5-dioxopyrrolidin-1-yl) (2S)-6-[(2-methylpropan-2-yl)oxycarbonylamino]-2-(phenylmethoxycarbonylamino)hexanoate
• CAS: 3338-34-9
• 化学式: C₂₃H₃₁N₃O₈
• mdl: MFCD00038822
• 分子量: 477.514
• InChiKey: NCFVVSXVXQRYFS-KRWDZBQOSA-N

物化性质

• 熔点：
  98-101 °C
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  34
• 可旋转键数：
  14
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.521
• 拓扑面积：
  140
• 氢给体数：
  2
• 氢受体数：
  8

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件为2-8℃，避光，并在惰性气体环境中保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Z-Lys(boc)-osu
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Z-Lys(boc)-osu
CAS number: 3338-34-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C23H31N3O8
Molecular weight: 477.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(alpha)-苄氧羰基-N-(epsilon)-叔丁氧羰基-L-赖氨酸琥珀酰亚胺基酯 在 钯 氢气 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 14.0h， 生成 H-Lys(Boc)-Pro-OH
  参考文献：
  名称：

  Synthesis of fragment 8–12 of the natural sequence of ACTH

  摘要：

  DOI：

  10.1007/bf00581605
• 作为产物：
  描述：

  (S)-2-amino-6-(tert-butoxycarbonylamino)hexanoic acid 在 copper(ll) sulfate pentahydrate 、 硫酸 、 sodium hydroxide 作用下， 以 水 、 乙酸乙酯 、 异丙醇 为溶剂， 反应 24.5h， 生成 N-(alpha)-苄氧羰基-N-(epsilon)-叔丁氧羰基-L-赖氨酸琥珀酰亚胺基酯
  参考文献：
  名称：

  DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS

  摘要：

  公开号：

  EP2397488B1

文献信息

• Angiotensin-converting enzyme inhibitors: Synthesis and structure-activity relationships of potent N-benzyloxycarbonyl tripeptide inhibitors.
  作者：Tadahiro SAWAYAMA、Masatoshi TSUKAMOTO、Takashi SASAGAWA、Kazuya NISHIMURA、Ryuichi YAMAMOTO、Takashi DEGUCHI、Kunihiko TAKEYAMA、Kanoo HOSOKI

  DOI：10.1248/cpb.37.2417

  日期：——

  (Z) tripeptide inhibitors of angiotensin-converting enzyme (ACE) was synthesized. The effect of varying the antepenultimate amino acid residue in this series on the biological activity was studied. Introduction of Lys and Orn residues at the P1 position provided the most potent inhibitors, 25a and 25b (IC50: 3.5 and 4.9 x 10(-9) M, respectively), which exhibited an oral antihypertensive activity. This

  合成了一系列新的含γ-D-Glu的血管紧张素转化酶（ACE）的N-苄氧基羰基（Z）三肽抑制剂。研究了改变该系列中前倒数第二个氨基酸残基对生物活性的影响。在P1位置引入Lys和Orn残基可提供最有效的抑制剂25a和25b（IC50：分别为3.5和4.9 x 10（-9）M），具有口服降压活性。该结果表明，在该系列中，P1位的碱性氨基酸残基在与ACE的S1亚位点的结合中起重要作用。评价了所选化合物的口服降压活性。
• POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE
  申请人：Elysium Therapeutics, Inc.

  公开号：US20170100390A1

  公开（公告）日：2017-04-13

  The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.

  这项发明提供了用于治疗或预防疼痛的组合物和方法。该发明提供了构造物，通过指定的胃肠酶在口服时直接或间接地水解构造物释放阿片类物质。该发明中构造物中的胃肠酶介导的阿片类物质释放被设计为在体内通过饱和或抑制机制在摄入过量时减弱。该发明进一步提供了对口服过量、化学篡改和通过非口服途径滥用高度抵抗的构造物。
• Synthesis and Conformational Analysis of Linear and Cyclic Peptides Containing Sugar Amino Acids
  作者：Erich Graf von Roedern、Elisabeth Lohof、Gerhard Hessler、Matthias Hoffmann、Horst Kessler

  DOI：10.1021/ja961068a

  日期：1996.1.1

  distinct turn structures. Linear and cyclic peptides involving SAAs have been prepared in solution as well as by solid phase synthesis. SAA1α and SAA2 were incorporated into two linear Leu-enkephalin analogs, replacing the natural Gly-Gly dipeptide. NMR studies provide evidence for the conformation-inducing effect of the carbohydrate moiety. SAA2 and SAA3 have been placed in cyclic hexapeptide analogs of

  糖氨基酸 (SAA) 被设计和合成为新的非肽肽模拟物，利用碳水化合物作为肽构建块。它们代表带有氨基和羧基官能团的类糖环结构，并且由于它们在刚性吡喃糖环中的不同取代模式，因此对肽的骨架具有特定的构象影响。已经合成了五种不同的 SAA（SAA1α、SAA1β、SAA2、SAA3 和 SAA4），它们显示出限制线性骨架构象或不同转角结构的能力。涉及 SAA 的线性和环状肽已在溶液中以及通过固相合成制备。SAA1α 和 SAA2 被整合到两个线性亮氨酸-脑啡肽类似物中，取代了天然的 Gly-Gly 二肽。NMR 研究为碳水化合物部分的构象诱导作用提供了证据。SAA2 和 SAA3 已被置于生长抑素的环状六肽类似物中；SAA4 被掺入模型肽中。的构造...
• IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE
  申请人：SOLSTICE BIOLOGICS, LTD.

  公开号：US20180312536A1

  公开（公告）日：2018-11-01

  Immunomodulating polynucleotides are disclosed. The immunomodulating polynucleotides may contain 5-modified uridine, 5-modified cytidine, a total of from 6 to 16 nucleotides, and/or one or more abasic spacers and/or internucleoside phosphotriesters. Also disclosed are conjugates containing a targeting moiety and one or more immunomodulating polynucleotides. The immunomodulating polynucleotides and conjugates may further contain one or more auxiliary moieties. Also disclosed are compositions containing the immunomodulating polynucleotides or the conjugates containing one or more stereochemically enriched internucleoside phosphorothioates. Further disclosed are pharmaceutical compositions containing the immunomodulating polynucleotides or the conjugates and methods of their use.

  免疫调节多核苷酸被披露。这些免疫调节多核苷酸可能包含5-修饰尿苷、5-修饰胞苷、总共6到16个核苷酸，和/或一个或多个缺失间隔子和/或核苷酸间磷三酯。还披露了含有靶向基团和一个或多个免疫调节多核苷酸的结合物。这些免疫调节多核苷酸和结合物可能进一步包含一个或多个辅助基团。还披露了含有这些免疫调节多核苷酸或含有一个或多个立体化富集的核苷酸间磷硫酸酯的结合物的组合物。进一步披露了含有这些免疫调节多核苷酸或结合物的药物组合物以及它们的使用方法。
• Process for preparing 1- [N²-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
  申请人：Linz Guenter

  公开号：US20050192230A1

  公开（公告）日：2005-09-01

  The present application relates to a process for preparing the CGRP-antagonist 1-[N 2 -[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine of formula by means of which this compound can be prepared in large amounts, in high yields and with high purity.

  本申请涉及一种制备CGRP拮抗剂1-[N2-[3,5-二溴-N-[[4-(3,4-二氢-2(1H)-氧喹唑啉-3-基)-1-哌啶基]羰基]-D-酪氨酰]-L-赖氨酰]-4-(4-吡啶基)-哌嗪的方法，通过该方法可以大量、高产率且高纯度地制备该化合物。